JP2016508984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508984A5 JP2016508984A5 JP2015549810A JP2015549810A JP2016508984A5 JP 2016508984 A5 JP2016508984 A5 JP 2016508984A5 JP 2015549810 A JP2015549810 A JP 2015549810A JP 2015549810 A JP2015549810 A JP 2015549810A JP 2016508984 A5 JP2016508984 A5 JP 2016508984A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745508P | 2012-12-21 | 2012-12-21 | |
| US61/745,508 | 2012-12-21 | ||
| US201361827325P | 2013-05-24 | 2013-05-24 | |
| US61/827,325 | 2013-05-24 | ||
| PCT/US2013/077139 WO2014100689A1 (en) | 2012-12-21 | 2013-12-20 | Anti-gdf15 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019007928A Division JP2019056018A (ja) | 2012-12-21 | 2019-01-21 | 抗ｇｄｆ１５抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508984A JP2016508984A (ja) | 2016-03-24 |
| JP2016508984A5 true JP2016508984A5 (OSRAM) | 2017-02-09 |
| JP6758832B2 JP6758832B2 (ja) | 2020-09-30 |
Family
ID=50069279
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549810A Active JP6758832B2 (ja) | 2012-12-21 | 2013-12-20 | 抗ｇｄｆ１５抗体 |
| JP2019007928A Withdrawn JP2019056018A (ja) | 2012-12-21 | 2019-01-21 | 抗ｇｄｆ１５抗体 |
| JP2021009528A Withdrawn JP2021061864A (ja) | 2012-12-21 | 2021-01-25 | 抗ｇｄｆ１５抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019007928A Withdrawn JP2019056018A (ja) | 2012-12-21 | 2019-01-21 | 抗ｇｄｆ１５抗体 |
| JP2021009528A Withdrawn JP2021061864A (ja) | 2012-12-21 | 2021-01-25 | 抗ｇｄｆ１５抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9175076B2 (OSRAM) |
| EP (2) | EP3689370A1 (OSRAM) |
| JP (3) | JP6758832B2 (OSRAM) |
| KR (1) | KR102208861B1 (OSRAM) |
| CN (1) | CN105073133B (OSRAM) |
| AR (1) | AR094271A1 (OSRAM) |
| AU (1) | AU2013364133B2 (OSRAM) |
| CA (1) | CA2896076C (OSRAM) |
| DK (1) | DK2934584T3 (OSRAM) |
| EA (1) | EA038645B1 (OSRAM) |
| ES (1) | ES2791183T3 (OSRAM) |
| MX (1) | MX370720B (OSRAM) |
| WO (1) | WO2014100689A1 (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| JP6501521B2 (ja) | 2012-08-24 | 2019-04-17 | 中外製薬株式会社 | ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| SI2900263T1 (sl) | 2012-09-26 | 2019-09-30 | Julius-Maximilians-Universitaet Wuerzburg | Monoklonska protitelesa proti rastnemu in diferenciacijskemu faktorju 15 (gdf-15) |
| CN105073133B (zh) | 2012-12-21 | 2021-04-20 | Aveo制药公司 | 抗gdf15抗体 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| RU2704285C2 (ru) | 2013-01-30 | 2019-10-25 | Нгм Байофармасьютикалз, Инк. | Композиции и способы применения для лечения метаболических расстройств |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| JP6509852B2 (ja) | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）の構築物 |
| US10261094B2 (en) * | 2013-10-31 | 2019-04-16 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| CN105934249A (zh) | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| CN107073088A (zh) | 2014-03-19 | 2017-08-18 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 免疫原性糖肽、包含所述糖肽的组合物及其用途 |
| PT3653644T (pt) * | 2014-03-26 | 2023-12-19 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro |
| GB2524552B (en) * | 2014-03-26 | 2017-07-12 | Julius-Maximilians-Universitãt Wurzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| GB2524553C (en) * | 2014-03-26 | 2017-07-19 | Julius-Maximilians-Universitãt Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| US20170137505A1 (en) * | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SG10201802098UA (en) | 2014-07-30 | 2018-04-27 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| EP3693004A1 (en) * | 2014-08-01 | 2020-08-12 | The Brigham and Women's Hospital, Inc. | An inhibitor of gdf-15 for use in treating fibrosis |
| US20170306008A1 (en) * | 2014-09-25 | 2017-10-26 | Aveo Pharmaceuticals, Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| CA2962859A1 (en) * | 2014-09-30 | 2016-04-07 | Universiteit Gent | A method of treating joint disease |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| CN115043945A (zh) | 2014-10-31 | 2022-09-13 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| HRP20240415T1 (hr) * | 2015-04-23 | 2025-05-23 | HaemaLogiX Ltd | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba |
| CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
| GB201512733D0 (en) * | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| EA201890850A1 (ru) | 2015-10-02 | 2018-09-28 | Юлиус-Максимилианс-Универзитет Вюрцбург | Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа |
| AU2016333538B2 (en) | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| EP3368567B1 (en) * | 2015-10-28 | 2025-10-01 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3411066A1 (en) * | 2016-02-01 | 2018-12-12 | Eli Lilly and Company | Parathyroid hormone anti-rankl antibody fusion compounds |
| JP2019510739A (ja) * | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Ｇｆｒａｌ受容体療法 |
| AU2017228489A1 (en) * | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| AU2017241161B2 (en) * | 2016-03-31 | 2022-05-26 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| JP7138567B2 (ja) * | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| KR20190035863A (ko) * | 2016-08-05 | 2019-04-03 | 알라코스 인크. | 암 치료를 위한 항Siglec-7 항체 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| EP3551214B1 (en) * | 2016-12-06 | 2024-03-13 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| KR102869563B1 (ko) | 2017-07-17 | 2025-10-10 | 얀센 바이오테크 인코포레이티드 | 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법 |
| WO2019140273A1 (en) * | 2018-01-11 | 2019-07-18 | Allakos, Inc. | Anti-siglec-7 antibodies having reduced effector function |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CA3096097A1 (en) | 2018-04-09 | 2019-10-17 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| WO2020033797A1 (en) * | 2018-08-09 | 2020-02-13 | The Wistar Institute | Anti-follicule stimulating hormone receptor antibodies |
| PE20211412A1 (es) * | 2018-08-20 | 2021-08-02 | Pfizer | Anticuerpos anti-gdf15, composiciones y metodos de uso |
| KR102238927B1 (ko) * | 2018-08-30 | 2021-04-12 | 서울대학교산학협력단 | 세포 내에서 nag-1 단백질의 이동을 조절하는 펩티드 및 이의 용도 |
| WO2020053147A1 (en) * | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| US20220372125A1 (en) * | 2019-10-02 | 2022-11-24 | Aslan Pharmaceuticals Pte. Ltd. | Antigen Specific Binding Domains and Antibody Molecules |
| WO2021111636A1 (ja) * | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗ｇｄｆ１５抗体 |
| CN114560938B (zh) * | 2020-03-30 | 2023-05-23 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
| AU2021284131B2 (en) * | 2020-06-04 | 2025-05-29 | Daegu Gyeongbuk Institute Of Science And Technology | GFRAL-antagonistic antibody and use thereof |
| AU2021367458B2 (en) * | 2020-10-30 | 2025-05-01 | Hideaki Hara | Gdf15 modulator for use in inhibition of ocular tissue fibrosis |
| IL302646A (en) | 2020-11-10 | 2023-07-01 | Catalym Gmbh | Anti-GDF15 antibody and dosage regimen for cancer treatment |
| US11845791B2 (en) | 2021-03-08 | 2023-12-19 | Medimmune, Llc | Antibodies directed against GDF-15 |
| EP4314071A1 (en) | 2021-03-31 | 2024-02-07 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| WO2023018803A1 (en) | 2021-08-10 | 2023-02-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| WO2023079430A1 (en) | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| KR20240134385A (ko) * | 2022-01-26 | 2024-09-09 | 윤난 베이야오 그룹 컴파니 리미티드 | 항-성장 분화 인자 15의 항체 분자 및 그의 응용 |
| CN119487065A (zh) | 2022-05-09 | 2025-02-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
| CN116041497A (zh) * | 2022-12-22 | 2023-05-02 | 杭州贤至生物科技有限公司 | 一种猫杯状病毒（fcv）重组蛋白单克隆抗体及制备方法 |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
| WO2025072516A1 (en) * | 2023-09-27 | 2025-04-03 | Aveo Pharmaceuticals, Inc. | Methods of reducing weight loss using anti-gdf15 antibodies |
| WO2025146488A1 (en) | 2024-01-05 | 2025-07-10 | Catalym Gmbh | Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| DE69637844D1 (de) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| CA2657302A1 (en) | 1998-10-07 | 2000-04-13 | Hermann Oppermann | Modified tgf-.beta. superfamily proteins |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| PT1179067E (pt) | 1999-05-17 | 2007-01-31 | Biopharm G Biotechnolo Entwi V | Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta |
| AU5018201A (en) | 2000-04-20 | 2001-11-07 | St Vincents Hospital Sydney Lt | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| JP2006515747A (ja) | 2002-11-01 | 2006-06-08 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| AU2003295424A1 (en) | 2002-11-08 | 2004-06-03 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US20060188889A1 (en) | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
| AU2004306783A1 (en) | 2003-10-10 | 2005-04-21 | That Corporation | Low-power integrated-circuit signal processor with wide dynamic range |
| EP1731171A4 (en) | 2004-03-26 | 2008-01-02 | Takeda Pharmaceutical | MEANS FOR THE PREVENTION / HEALING OF RESPIRATORY DISEASES |
| ES2555956T3 (es) | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| CA2534871C (en) | 2006-02-15 | 2015-08-04 | The Ohio State University Research Foundation | Three-gene test to differentiate malignant from benign thyroid nodules |
| US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
| CN106018820B (zh) | 2006-08-04 | 2018-04-27 | 汉诺威医学院 | 根据gdf-15评价心脏介入风险的工具与方法 |
| EP1884777A1 (en) | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| JP2010536717A (ja) * | 2007-08-16 | 2010-12-02 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法 |
| CN101896192A (zh) | 2007-10-09 | 2010-11-24 | 圣文森特医院悉尼有限公司 | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 |
| EP2103943A1 (en) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs |
| JP2011523051A (ja) | 2008-05-20 | 2011-08-04 | エフ．ホフマン−ラ ロシュ アーゲー | １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５ |
| GB0902793D0 (en) * | 2009-02-20 | 2009-04-08 | Univ Gent | GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes |
| US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| GB201004739D0 (en) | 2010-03-22 | 2010-05-05 | Prosidion Ltd | Receptor modulators |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN105073133B (zh) | 2012-12-21 | 2021-04-20 | Aveo制药公司 | 抗gdf15抗体 |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
-
2013
- 2013-12-20 CN CN201380073317.1A patent/CN105073133B/zh active Active
- 2013-12-20 EP EP20156883.9A patent/EP3689370A1/en active Pending
- 2013-12-20 JP JP2015549810A patent/JP6758832B2/ja active Active
- 2013-12-20 EP EP13827058.2A patent/EP2934584B1/en active Active
- 2013-12-20 CA CA2896076A patent/CA2896076C/en active Active
- 2013-12-20 KR KR1020157019881A patent/KR102208861B1/ko active Active
- 2013-12-20 EA EA201591198A patent/EA038645B1/ru unknown
- 2013-12-20 WO PCT/US2013/077139 patent/WO2014100689A1/en not_active Ceased
- 2013-12-20 AR ARP130105017A patent/AR094271A1/es active IP Right Grant
- 2013-12-20 ES ES13827058T patent/ES2791183T3/es active Active
- 2013-12-20 DK DK13827058.2T patent/DK2934584T3/da active
- 2013-12-20 MX MX2015007751A patent/MX370720B/es active IP Right Grant
- 2013-12-20 AU AU2013364133A patent/AU2013364133B2/en active Active
- 2013-12-20 US US14/137,415 patent/US9175076B2/en active Active
-
2015
- 2015-09-24 US US14/863,870 patent/US9725505B2/en active Active
-
2017
- 2017-07-20 US US15/655,263 patent/US10597444B2/en active Active
-
2019
- 2019-01-21 JP JP2019007928A patent/JP2019056018A/ja not_active Withdrawn
-
2020
- 2020-03-19 US US16/824,034 patent/US11725047B2/en active Active
-
2021
- 2021-01-25 JP JP2021009528A patent/JP2021061864A/ja not_active Withdrawn
-
2023
- 2023-06-16 US US18/336,713 patent/US12258391B2/en active Active
-
2025
- 2025-02-07 US US19/048,087 patent/US20250277019A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508984A5 (OSRAM) | ||
| JP2019524693A5 (OSRAM) | ||
| JP2020522513A5 (OSRAM) | ||
| JP2019513725A5 (OSRAM) | ||
| JP2011520898A5 (OSRAM) | ||
| AR080291A1 (es) | Anticuerpos antagonistas anti receptor de il-7 y procedimientos | |
| JP2010527356A5 (OSRAM) | ||
| JP2018503380A5 (OSRAM) | ||
| JP2018121657A5 (OSRAM) | ||
| JP2015163068A5 (OSRAM) | ||
| JP2013527762A5 (OSRAM) | ||
| JP2017531427A5 (OSRAM) | ||
| JP2016539096A5 (OSRAM) | ||
| JP2012522523A5 (OSRAM) | ||
| JPWO2019215728A5 (OSRAM) | ||
| US12312400B2 (en) | Engineered anti-il-2 antibodies | |
| JP2017523786A5 (OSRAM) | ||
| JP2012520308A5 (OSRAM) | ||
| JP2019527194A5 (OSRAM) | ||
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| JP2016519650A5 (OSRAM) | ||
| JP2015509960A5 (OSRAM) | ||
| JP2019512207A5 (OSRAM) | ||
| JP2021508707A5 (OSRAM) | ||
| CN114945594A (zh) | 抗lilrb1抗体及其用途 |